Published in Infect Agent Cancer on September 01, 2014
Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy. Infect Agent Cancer (2015) 0.76
Nonavalent human papillomavirus vaccination as a treatment for warts in an immunosuppressed adult. JAAD Case Rep (2017) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet (2006) 7.83
Worldwide burden of cervical cancer in 2008. Ann Oncol (2011) 5.66
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med (2008) 3.02
Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ (2011) 2.95
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Chapter 8: Screening for cervical cancer in developing countries. Vaccine (2006) 2.35
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine (2010) 1.94
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine (2011) 1.91
Sexual behavior, knowledge and information sources of very young adolescents in four sub-Saharan African countries. Afr J Reprod Health (2007) 1.65
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health (2007) 1.63
Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin (2011) 1.63
Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 –- conclusions and recommendations. Wkly Epidemiol Rec (2014) 1.50
Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev (2007) 1.45
Introducing human papillomavirus vaccines - questions remain. Ann Med (2008) 1.14
Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer (2011) 1.03
Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine: a randomized trial in 10-25-year-old HIV-Seronegative African girls and young women. J Infect Dis (2012) 0.94
Beyond validity and reliability: meaning-in-context of adolescents' self-reports of sexual behavior. J Adolesc Health (2009) 0.88
Self-reported sexual behaviour among adolescent girls in Uganda: reliability of data debated. Afr Health Sci (2011) 0.87
Risk of seropositivity to multiple oncogenic human papillomavirus types among human immunodeficiency virus-positive and -negative Ugandan women. J Gen Virol (2011) 0.85
No difference in sexual behavior of adolescent girls following Human Papilloma Virus vaccination: a case study two districts in Uganda; Nakasongola and Luwero. BMC Public Health (2014) 0.83
Vaccines against human papillomavirus in low and middle income countries: a review of safety, immunogenicity and efficacy. Infect Agent Cancer (2015) 0.76